ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
News Jul 29, 2014
ELC Group has announced the appointment of Inna Demidova as a Senior Regulatory Affairs Expert for Russia and the Commonwealth of Independent States (CIS).
Previously with Ferring Pharmaceuticals as Regulatory Affairs Manager, Inna Demidova is an expert on both the Russian and CIS regulatory environment and clinical trials organizations, having managed numerous teams through rigorous registration, QA and medical activities. Inna Demidova will also be tasked with heading ELC Group’s planned Moscow office, due to open later in 2014.
The establishment of a regional base in Russia comes off the back of a record year of growth and revenue performance for ELC Group, with office openings in Brazil and China set to follow soon.
Commenting on the appointment, ELC Group’s CEO Marco Rubenstein said: “We are very pleased to welcome Inna to the ELC Group team. Her knowledge and experience of the Russian and CIS territories is extremely impressive and we look forward to rapidly expanding our presence under her expert guidance.”
Inna Demidova added: “I am very excited to be joining ELC Group as Head of Regulatory Affairs for Russia and CIS, and to bringing ELC Group’s market-leading services to these crucial markets.”
Inna Demidova studied Pharmacology at Medical State University in Almaty, Kazakhstan, before later receiving a Bachelor of Science from Portland Business College.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE